港股异动 | 先健科技(01302)涨近6% 主动脉覆膜支架系统获国家药监局正式注册批准

智通财经
14 Feb

智通财经APP获悉,先健科技(01302)涨近6%,截至发稿,涨5.84%,报1.45港元,成交额626.5万港元。

消息面上,先健科技发布公告,于2025年2月8日,由中国医学科学院阜外医院舒畅教授领衔,与集团共同研发的主动脉覆膜支架系统获中国国家药品监督管理局正式注册批准。该产品为国家药品监督管理局批准的首款明确适用于烟囱技术的主动脉覆膜支架系统,为累及主动脉弓部病变的患者提供了一种操作简便、安全有效、解剖适应广泛的治疗新选择。

据介绍,该产品由AnkuraTM Pro主动脉主体覆膜支架系统和LonguetteTM 主动脉分支覆膜支架系统组成。AnkuraTM Pro采用ePTFE 覆膜,并提供0-10多种锥度,可满足不同的临床需求。LonguetteTM裙边支架采用带外层裙边的双层结构设计,外层裙边可在支架释放后有效填补分支支架与主动脉支架的间隙,预期可以防止和减少内漏发生,降低并发症风险。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10